@article{puhl_gomes_damasceno_fritch_levi_johnson_scholle_premkumar_hurst_lee-montiel_et al._2022, title={Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice}, volume={7}, ISSN={["2470-1343"]}, DOI={10.1021/acsomega.2c02794}, abstractNote={The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid, and molnupiravir), or in advanced clinical trials. Vandetanib is a kinase inhibitor which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), as well as the RET-tyrosine kinase. In the current study, it was tested in different cell lines and showed promising results on inhibition versus the toxic effect on A549-hACE2 cells (IC50 0.79 μM) while also showing a reduction of >3 log TCID50/mL for HCoV-229E. The in vivo efficacy of vandetanib was assessed in a mouse model of SARS-CoV-2 infection and statistically significantly reduced the levels of IL-6, IL-10, and TNF-α and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load. Vandetanib also decreased CCL2, CCL3, and CCL4 compared to the infected animals. Vandetanib additionally rescued the decreased IFN-1β caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved anticancer drug vandetanib is worthy of further assessment as a potential therapeutic candidate to block the COVID-19 cytokine storm.}, number={36}, journal={ACS OMEGA}, author={Puhl, Ana C. and Gomes, Giovanni F. and Damasceno, Samara and Fritch, Ethan J. and Levi, James A. and Johnson, Nicole J. and Scholle, Frank and Premkumar, Lakshmanane and Hurst, Brett L. and Lee-Montiel, Felipe and et al.}, year={2022}, month={Sep}, pages={31935–31944} }